Genscript Biotech

Genscript Biotech's reported carbon emissions

GenScript Biotech, a research and development services firm with its US headquarters, reported significant carbon emissions across its operations. For the year 2024, the company's total greenhouse gas emissions were approximately 520,700,000 kg CO2e. This figure comprises Scope 1 emissions of about 39,376,800 kg CO2e, Scope 2 emissions (market-based) of approximately 114,034,820 kg CO2e, and Scope 3 emissions totalling around 387,589,810 kg CO2e. In 2023, GenScript Biotech's total emissions were approximately 452,260,000 kg CO2e. This breakdown includes Scope 1 emissions of about 48,821,780 kg CO2e, Scope 2 emissions (market-based) of approximately 83,758,360 kg CO2e, and Scope 3 emissions of around 314,658,760 kg CO2e. Prior to 2023, the company's reported emissions data primarily focused on Scope 1 and Scope 2. In 2021, total Scope 1 and Scope 2 emissions were approximately 77,476,220 kg CO2e, with Scope 1 at about 1,302,900 kg CO2e and Scope 2 at approximately 76,173,320 kg CO2e. For 2020, total Scope 1 and Scope 2 emissions were roughly 49,422,560 kg CO2e, consisting of Scope 1 emissions of approximately 1,116,640 kg CO2e and Scope 2 emissions of about 48,305,920 kg CO2e. In 2019, the combined Scope 1 and Scope 2 emissions stood at approximately 48,942,850 kg CO2e, with Scope 1 emissions at about 4,837,130 kg CO2e and Scope 2 emissions at approximately 44,105,720 kg CO2e. The earliest available data for 2016 indicates Scope 2 emissions of about 7,589,000 kg CO2e. GenScript Biotech's emissions reports for 2023 and 2024 note that data for certain Scope 3 categories, including purchased goods and services, business travel, and employee commute, were missing. The company has not publicly disclosed specific reduction targets or commitments to science-based initiatives.